Abigail Langsam represents clients in a host of intellectual property matters, including patent litigations and intellectual property transactions. She is experienced in every stage of litigation, including discovery management, trial, and appeal, and has practiced in both state and federal court. Ms. Langsam regularly advises on patent due diligence investigations, and counsels clients in connection with licenses and acquisitions. Her patent matters have spanned technologies including small molecule pharmaceuticals, biologic drug products, pharmaceutical compositions, drug delivery technology, telecommunications, biofuels, and computer systems.

Experience

  • Novartis in multiple Hatch-Waxman patent litigations relating to Novartis' Gleevec® drug product, indicated for the treatment of chronic myeloid leukemia. Novartis Pharmaceuticals Corp. and Novartis AG v. Roxane Laboratories et al. (D. Del.).
  • Time Warner Cable in patent litigation relating to on-demand television. Broadband iTV, Inc. v. Hawaiian Telcom, Inc., Oceanic Time Warner Cable LLC and Time Warner Cable, Inc. (D. Haw.).
  • Novartis in patent litigation relating to leukemia immunotherapy with Chimeric Antigen Receptor modified T cells. Managed all discovery in this complex litigation. Trustees of the University of Pennsylvania and Novartis Pharmaceuticals Corporation v. St. Jude Children's Research Hospital, Inc. and Juno Therapeutics, Inc. (E.D. Pa.).
  • Pfizer in patent litigation concerning Pfizer's Celebrex® drug product. Worked extensively with experts and devised winning claim construction strategy. G.D. Searle LLC and Pfizer Asia Pacific PTE. LTD. v. Lupin Pharmaceuticals, Inc., et. al. (D. Va.).
  • Sanofi-Aventis as a member of the trial team in patent litigation relating to Sanofi's Allegra® drug products. Aventis Pharmaceuticals, Inc. v. Dr. Reddy's Laboratories Ltd. et al. (D.N.J.).
  • Vivelle Ventures, Noven Pharmaceuticals, and Novartis in Hatch-Waxman litigation concerning the Vivelle Dot® transdermal estradiol drug product. Vivelle Ventures, Noven Pharmaceuticals, and Novartis Pharmaceuticals Corporation v. Mylan Technologies, et al. (S.D.N.Y).
  • Qinetiq Group in patent litigation relating to metal detector technology. Mednovus, Inc. and First Texas Holdings Corp. v. Qinetiq Group PLC et al. (C.D. Cal).
  • Butamax and du Pont in patent litigation relating to biofuels technology. Butamax™ Advanced Biofuels LLC and du Pont de Nemours and Company v. Gevo, Inc. (D. Del).
  • CLS Bank International in landmark patent litigation relating to computerized methods of exchanging financial obligations. CLS Bank International v. Alice Corporation PTY. LTD. (D.D.C.).
  • Roche defendants in patent litigation relating to recombinant human erythropoietin therapy. Amgen v. F. Hoffman-La Roche Ltd., Roche Diagnostics Gmbh, and Hoffman-La Roche Inc. (D. Mass.).
  • Pfizer in first Hatch-Waxman litigation concerning Pfizer's Celebrex® drug product. Pfizer Inc. et al. v. Teva Pharmaceuticals USA, Inc. (D.N.J.).

Credentials

Education
  • JD, Fordham University School of Law, 2004, cum laude
  • BA, Neuroscience, Wesleyan University, 1999
Admissions
  • New York
  • US District Court, Eastern District of New York
  • US District Court, Southern District of New York
Overview

Email Disclaimer